407 related articles for article (PubMed ID: 30426287)
1. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.
LaRocca CJ; Warner SG
Clin Transl Med; 2018 Nov; 7(1):35. PubMed ID: 30426287
[TBL] [Abstract][Full Text] [Related]
2. Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy.
Lv P; Chen X; Fu S; Ren E; Liu C; Liu X; Jiang L; Zeng Y; Wang X; Liu G
Biomater Sci; 2021 Nov; 9(22):7392-7401. PubMed ID: 34751685
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
Sivanandam V; LaRocca CJ; Chen NG; Fong Y; Warner SG
Mol Ther Oncolytics; 2019 Jun; 13():93-106. PubMed ID: 31080879
[TBL] [Abstract][Full Text] [Related]
4. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.
Zhao Y; Liu Z; Li L; Wu J; Zhang H; Zhang H; Lei T; Xu B
Front Microbiol; 2021; 12():707290. PubMed ID: 34367111
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.
Sato-Dahlman M; LaRocca CJ; Yanagiba C; Yamamoto M
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455560
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
[TBL] [Abstract][Full Text] [Related]
9. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.
Hoare J; Campbell N; Carapuça E
Porto Biomed J; 2018 Aug; 3(1):e7. PubMed ID: 31595233
[TBL] [Abstract][Full Text] [Related]
13. From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review.
Kuryk L; Bertinato L; Staniszewska M; Pancer K; Wieczorek M; Salmaso S; Caliceti P; Garofalo M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092131
[TBL] [Abstract][Full Text] [Related]
14. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.
Simpson GR; Relph K; Harrington K; Melcher A; Pandha H
Oncolytic Virother; 2016; 5():1-13. PubMed ID: 27579292
[TBL] [Abstract][Full Text] [Related]
16. The Role of Oncolytic Viruses in the Treatment of Melanoma.
Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM
Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781
[TBL] [Abstract][Full Text] [Related]
17. Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies.
Gujar S; Pol JG; Kroemer G
Oncoimmunology; 2018; 7(8):e1442169. PubMed ID: 30221036
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.
Sampath P; Thorne SH
Oncolytic Virother; 2015; 4():75-82. PubMed ID: 27512672
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virus immunotherapy: future prospects for oncology.
Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
